律师事务所调查Humacyte证券欺诈行为,指控虚假陈述延误林业发展局的批准。 Law firms investigate Humacyte for securities fraud, alleging false statements delayed FDA approval.

Rosen律师事务所和Faruqi & Faruqi正在调查Humacyte公司证券欺诈案,指控该公司对其Durham设施作虚假陈述,导致林业发展局推迟核准其血管产品。 Rosen Law Firm and Faruqi & Faruqi are investigating Humacyte, Inc. for securities fraud, alleging the company made false statements about its Durham facility, leading to delayed FDA approval of its vascular product. 鼓励2024年5月10日至10月17日期间购买证券的投资者加入诉讼或讨论潜在债权。 Investors who bought securities between May 10 and October 17, 2024, are encouraged to join the lawsuit or discuss potential claims. 加入集体诉讼的截止日期是2025年1月17日。 The deadline to join the class action is January 17, 2025.